Thyroid hormones, including TIROSINT, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic ami...
Administer TIROSINT as a single daily oral dose, on an empty stomach, one-half to one hour before breakfast. Administer TIROSINT at least 4 hours before or after drugs known to interfere with TIROSINT absorption [see Drug Interactions (7.1) ] Evaluate the need for dose adjustments when regularly administering within an hour of certain foods that may affect TIROSINT absorption [see Drug Interactions (7.9) and Clini...
TIROSINT (levothyroxine sodium) capsules are amber-colored, round/biconvex capsules, imprinted with a dosage strength specific letter on one side and containing a viscous amber-colored liquid. They are supplied as follows: Table 7: TIROSINT Packaging Description - Boxes of 28 capsules, consisting of 4 blisters with 7 capsules each Strength (mcg) Color Shown on box and blister packing, not on individual capsules. I...
www.fda.gov/medwatch
www.poison.org
www.tirosint.comHypothyroidism
TIROSINT is indicated as a replacement therapy in adults and pediatric patients 6 years and older with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression
TIROSINT is indicated as an adjunct to surgery and radioiodine therapy in the management of adults and pediatric patients 6 years and older with thyrotropin-dependent well-differentiated thyroid cancer.
Limitations of Use:
Administer TIROSINT as a single daily oral dose, on an empty stomach, one-half to one hour before breakfast.
Administer TIROSINT at least 4 hours before or after drugs known to interfere with TIROSINT absorption [see Drug Interactions (7.1)]
Evaluate the need for dose adjustments when regularly administering within an hour of certain foods that may affect TIROSINT absorption [see Drug Interactions (7.9) and Clinical Pharmacology (12.3)].
Swallow TIROSINT capsules whole, do not cut or crush capsules.
The dose of TIROSINT for hypothyroidism or pituitary TSH suppression depends on a variety of factors including the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food, and the specific nature of the condition being treated [see Dosage and Administration (2.3), Warnings and Precautions (5), and Drug Interactions (7)]. Dosing must be individualized to account for these factors and dose adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4)].
The peak therapeutic effect of a given dose of TIROSINT may not be attained for 4 to 6 weeks.
Primary Hypothyroidism in Adults and in Adolescents in Whom Growth and Puberty are Complete
Start TIROSINT at the full replacement dose in otherwise healthy, non-elderly individuals who have been hypothyroid for only a short time (such as a few months).The average full replacement dose of TIROSINT is approximately 1.6 mcg per kg per day (for example: 100-125 mcg per day for a 70 kg adult).
Adjust the dose by 12.5 to 25 mcg increments every 4 to 6 weeks until the patient is clinically euthyroid and the serum TSH returns to normal. Doses greater than 200 mcg per day are seldom required. An inadequate response to daily doses greater than 300 mcg per day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.
For elderly patients or patients with underlying cardiovascular disease, start with a dose of 12.5 to 25 mcg per day. Increase the dose every 6 to 8 weeks, as needed, until the patient is clinically euthyroid and the serum TSH returns to normal. The full replacement dose of TIROSINT may be less than 1 mcg per kg per day in elderly patients.
In patients with severe longstanding hypothyroidism, start with a dose of 12.5 to 25 mcg per day. Adjust the dose in 12.5 to 25 mcg increments every 2 to 4 weeks until the patient is clinically euthyroid and the serum TSH level is normalized.
Secondary or Tertiary Hypothyroidism
Start TIROSINT at the full replacement dose in otherwise healthy, non-elderly individuals. Start with a lower dose in elderly patients with underlying cardiovascular disease or patients with severe longstanding hypothyroidism as described above. Serum TSH is not a reliable measure of TIROSINT dose adequacy in patients with secondary or tertiary hypothyroidism, and should not be used to monitor therapy. Use the serum free-T4 level to monitor adequacy of therapy in this patient population. Titrate TIROSINT dosing per above instructions until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range.
Pediatric Dosage - Congenital or Acquired Hypothyroidism
Only administer TIROSINT to pediatric patients 6 years and older who are able to swallow an intact capsule.
The recommended daily dose of TIROSINT in pediatric patients with hypothyroidism is based on body weight and changes with age as described in Table 1. Start TIROSINT at the full daily dose in most pediatric patients. Start at a lower dose in children at risk for hyperactivity (see below). Monitor for clinical and laboratory response [see Dosage and Administration (2.4)].
| Age | Daily Dose Per Kg Body Weight* |
|---|---|
| 6-12 years | 4-5 mcg/kg/day |
| Greater than 12 years but growth and puberty incomplete | 2-3 mcg/kg/day |
| Growth and puberty complete | 1.6 mcg/kg/day |
* The dose should be adjusted based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)].
Children at risk for hyperactivity: To minimize the risk of hyperactivity in children, start at one-fourth the recommended full replacement dose, and increase on a weekly basis by one-fourth the full-recommended replacement dose until the full recommended replacement dose is reached.
Pregnancy
Preexisting Hypothyroidism: TIROSINT dose requirements may increase during pregnancy. Measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at a minimum, during each trimester of pregnancy. In patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. For patients with serum TSH above the normal trimester specific range, increase the dose of TIROSINT by 12.5 to 25 mcg per day and measure TSH every four weeks until a stable TIROSINT dose is reached and serum TSH is within the normal trimester specific range. Reduce TIROSINT dosage to pre-pregnancy levels immediately after delivery and measure serum TSH levels 4 to 8 weeks postpartum to ensure the TIROSINT dose is appropriate.
New Onset Hypothyroidism: Normalize thyroid function as rapidly as possible. In patients with moderate to severe signs and symptoms of hypothyroidism, start TIROSINT at the full replacement dose (1.6 mcg per kg body weight per day). In patients with mild hypothyroidism (TSH < 10 mIU per Liter), start TIROSINT at 1.0 mcg per kg body weight per day. Evaluate serum TSH every 4 weeks and adjust TIROSINT dosage until serum TSH is within the normal trimester specific range [see Use in Specific Populations (8.1)].
TSH Suppression in Well-Differentiated Thyroid Cancer
Generally, TSH is suppressed to below 0.1 mIU per Liter, and this usually requires a TIROSINT dose of greater than 2 mcg per kg per day. However, in patients with high-risk tumors, the target level for TSH suppression may be lower.
Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of TIROSINT may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.
Adults
In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dose. In patients on a stable and appropriate replacement dose, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient's clinical status.
Pediatrics
In patients with congenital hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in children is as follows: at 2 and 4 weeks after the initiation of treatment 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dose stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of mental and physical growth and development, and bone maturation at regular intervals.
While the general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of the pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of TIROSINT therapy and/or of the serum TSH to decrease below 20 mIU per Liter within 4 weeks may indicate the child is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of TIROSINT [see Warnings and Precautions (5.4) and Use in Specific Populations (8.4)].
Secondary (Pituitary) and Tertiary (Hypothalamic) Hypothyroidism
Monitor serum free-T4 levels maintain in the upper half of the normal range in these patients.
TIROSINT capsules are amber-colored, round/biconvex capsules, imprinted with a dosage strength specific letter on one side and containing a viscous amber-colored liquid and are available as follows:
| Strength (mcg) | Imprint Code |
|---|---|
| 13 | A |
| 25 | E |
| 50 | G |
| 75 | H |
| 88 | J |
| 100 | K |
| 112 | M |
| 125 | N |
| 137 | P |
| 150 | S |
| 175 | U |
| 200 | Y |
TIROSINT is contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.3)].
Overtreatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate TIROSINT therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration (2.3) and Use in Specific Populations (8.5)].
Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive TIROSINT therapy. Monitor patients receiving concomitant TIROSINT and sympathomimetic agents for signs and symptoms of coronary insufficiency. If cardiac symptoms develop or worsen, reduce the TIROSINT dose or withhold it for one week and restart at a lower dose.
Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.
Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy precipitate an acute adrenal crisis in patient with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with TIROSINT [see Contraindications (4)].
TIROSINT has a narrow therapeutic index. Over- or under-treatment with TIROSINT may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and on glucose and lipid metabolism. Titrate the dose of TIROSINT carefully and monitor response to titration to avoid these effects [see Dosage and Administration (2.4)]. Monitor for the presence of drug or food interactions when using TIROSINT and adjust the dose as necessary [see Drug Interactions (7) and Clinical Pharmacology (12.3)].
Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy [see Drug Interactions (7.2)].
Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of TIROSINT that achieves the desired clinical and biochemical response to mitigate against this risk.
Adverse reactions associated with TIROSINT therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5) and Overdosage (10)]. They include the following:
Seizures have been reported rarely with the institution of levothyroxine therapy.
Adverse Reactions in Children
Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height.
Hypersensitivity Reactions
Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various GI symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.
Many drugs can exert effects thyroid hormone pharmacokinetics (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to TIROSINT (see Tables 2 to 5 below).
| Potential impact: Concurrent use may reduce the efficacy of TIROSINT by binding and delaying or preventing absorption, potentially resulting in hypothyroidism | |
|---|---|
| Drug or Drug Class | Effect |
| Calcium Carbonate Ferrous Sulfate | Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. Administer TIROSINT at least 4 hours apart from these agents. |
| Orlistat | Monitor patients treated concomitantly with orlistat and TIROSINT for changes in thyroid function. |
| Bile Acid Sequestrants -Colesevelam -Cholestyramine -Colestipol Ion Exchange Resins -Kayexalate -Sevelamer | Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer TIROSINT at least 4 hours prior to these drugs or monitor thyrotropin (TSH) levels. |
| Other drugs: Proton Pump Inhibitors Sucralfate Antacids - Aluminum & Magnesium Hydroxides - Simethicone | Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately |
| Drug or Drug Class | Effect |
|---|---|
| Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen | These drugs may increase serum thyroxine-binding globulin (TBG) concentration. |
| Androgens / Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid | These drugs may decrease serum TBG concentration. |
| Potential impact (below): Administration of these agents with TIROSINT results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations. | |
| Salicylates (> 2 g/day) | Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. |
| Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs - Fenamates | These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increased free-T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free-T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters. |
| Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased TIROSINT requirements. | |
|---|---|
| Drug or Drug Class | Effect |
| Phenobarbital Rifampin | Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine. |
| Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased. | |
|---|---|
| Drug or Drug Class | Effect |
| Beta-adrenergic antagonists (e.g., Propranolol > 160 mg/day) | In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. |
| Glucocorticoids (e.g., Dexamethasone ≥ 4 mg/day) | Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see Table 3 above). |
| Other: Amiodarone | Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decrease or normal free-T3) in clinically euthyroid patients. |
Addition of TIROSINT therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Careful monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [see Warnings and Precautions (5.5)].
TIROSINT increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the TIROSINT dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.
TIROSINT may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.
Concurrent use of tricyclic (e.g., Amitriptyline) or tetracyclic (e.g., Maprotiline) antidepressants and TIROSINT may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. TIROSINT may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on TIROSINT may result in increased TIROSINT requirements.
Concurrent use of ketamine and TIROSINT may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.
Concurrent use of sympathomimetics and TIROSINT may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.
Consumption of certain foods may affect TIROSINT absorption thereby necessitating adjustments in dosing [see Dosage and Administration (2.1)]. Soybean flour (infant formula), cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of TIROSINT from the GI tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.
Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.
Risk Summary
Experience with levothyroxine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages [see Data]. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since thyroid-stimulating hormone (TSH) levels may increase during pregnancy, TSH should be monitored and TIROSINT dosage adjusted during pregnancy [see Clinical Considerations]. There are no animal studies conducted with levothyroxine during pregnancy. TIROSINT should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Disease-Associated Maternal and/or Embryo/Fetal Risk
Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.
Dose Adjustments During Pregnancy and the Postpartum Period
Pregnancy may increase TIROSINT requirements. Serum TSH level should be monitored and the TIROSINT dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the TIROSINT dosage should return to the pre-pregnancy dose immediately after delivery[see Dosage and Administration (2.3)].
Data
Human Data
Levothyroxine is approved for use as a replacement therapy for hypothyroidism. There is a long experience of levothyroxine use in pregnant women, including data from post-marketing studies that have not reported increased rates of fetal malformations, miscarriages or other adverse maternal or fetal outcomes associated with levothyroxine use in pregnant women.
Risk Summary
Limited published studies report that levothyroxine is present in human milk. However, there is insufficient information to determine the effects of levothyroxine on the breastfed infant and no available information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TIROSINT and any potential adverse effects on the breastfed infant from TIROSINT or from the underlying maternal condition.
TIROSINT is indicated for use in pediatric patients 6 years and older. The initial dose of TIROSINT varies with age and body weight. Dosing adjustments are based on an assessment of the individual patient's clinical and laboratory parameters [see Dosage and Administration (2.3, 2.4)]
In children in whom a diagnosis of permanent hypothyroidism has not been established, discontinue TIROSINT administration for a trial period. Obtain serum T4 and TSH levels at the end of the trial period, and use laboratory test results and clinical assessments to guide diagnosis and treatment, if warranted.
Congenital Hypothyroidism [see Dosage and Administration (2.3, 2.4)]
Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, initiate levothyroxine therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients.
Closely monitor children during the first two weeks of TIROSINT therapy for cardiac overload and arrhythmias.
Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment may adversely affect the tempo of brain maturation and accelerate the bone age with resultant premature closure of the epiphyses and compromised adult stature.
Acquired Hypothyroidism in Pediatric Patients
Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.
Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height.
Because of the increased prevalence of cardiovascular disease among the elderly, initiate TIROSINT therapy at less than the full replacement dose [see Warnings and Precautions (5.1) and Dosage and Administration (2.3) ]. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly.
The signs and symptoms of overdosage are those of hyperthyroidism [see Warnings and Precautions (5) and Adverse Reactions (6)]. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year-old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.
Reduce the TIROSINT dose or discontinue temporarily if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient's medical status.
For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.
TIROSINT (levothyroxine sodium) capsules for oral use contain synthetic L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is chemically identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of C15H10I4NNaO4 • x H2O (where x = 5), molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:
TIROSINT (levothyroxine sodium) capsules are amber-colored, round/biconvex capsules containing a viscous amber-colored liquid.
The inactive ingredients in TIROSINT are gelatin, glycerin and water.
Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.
The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.
Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.
Absorption
Absorption of orally administered T4 from the gastrointestinal (GI) tract ranges from 40% to 80%. The majority of the levothyroxine dose is absorbed from the jejunum and upper ileum. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases the bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption. [see Drug Interactions (7)]
Distribution
Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and thyroxine-binding albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins [see Drug Interactions (7)]. Thyroid hormones do not readily cross the placental barrier [see Use in Specific Populations (8.1)].
Elimination
Metabolism
T4 is slowly eliminated (see Table 6). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.
Excretion
Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.
Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of levothyroxine sodium.
TIROSINT (levothyroxine sodium) capsules are amber-colored, round/biconvex capsules, imprinted with a dosage strength specific letter on one side and containing a viscous amber-colored liquid. They are supplied as follows:
| Strength (mcg) | Color* | Imprint Code | NDC |
|---|---|---|---|
| 13 | Green | A | 24090-490-84 |
| 25 | Orange | E | 24090-491-84 |
| 50 | White | G | 24090-492-84 |
| 75 | Purple | H | 24090-493-84 |
| 88 | Olive | J | 24090-494-84 |
| 100 | Yellow | K | 24090-495-84 |
| 112 | Rose | M | 24090-496-84 |
| 125 | Brown | N | 24090-497-84 |
| 137 | Turquoise | P | 24090-498-84 |
| 150 | Blue | S | 24090-499-84 |
| 175 | Lilac | U | 24090-500-84 |
| 200 | Pink | Y | 24090-501-84 |
* Shown on box and blister packing, not on individual capsules.
The dosage strength on each box is clearly identified in several locations, and is associated with a distinct color. The color of the circles on the blister is the same color as on the box. Each blister pack contains 7 capsules placed in individual cavities labeled with the dosage strength, the product name (TIROSINT), and an abbreviation for the day of the week on which the capsule is taken.
Store at 25°C (77°F); excursions permitted to 15°-30°C (59-86°F) [see USP Controlled Room Temperature]. TIROSINT capsules should be protected from heat, light and moisture.
Do not separate the individual cavities containing the drug from the intact blister as important information may be lost (i.e., manufacturer/distributor names, distributor contact phone number, lot number, and expiration date), and do not remove the individual capsules from blister packaging until ready to use.
Advise the patient and/or the caregiver to read the FDA-approved patient labeling (Patient Information Sheet).
Dosing and Administration
Important Information
Adverse Reactions
Manufactured for Akrimax Pharmaceuticals, LLC by:
IBSA Institut Biochimique SA
6915 Pambio-Noranco
Switzerland
Distributed by:
Akrimax Pharmaceuticals, LLC,
Cranford, NJ07016
USA
Version April 2017
FI/164 9004
Ed. V/04.17
1047F004 Rev 04/17
| This Patient Information has been approved by the U.S. Food and Drug Administration | Issued: April 2017 | ||
| PATIENT INFORMATION TIROSINT® [tee-row-sent] (levothyroxine sodium) capsules, for oral use | |||
What is the most important information I should know about TIROSINT?
| |||
| What is TIROSINT? TIROSINT is a prescription medicine that contains a hormone called levothyroxine which is normally produced by the thyroid gland. TIROSINT is used to treat adults and children 6 years of age or older:
TIROSINT should not be used to treat people who are recovering from swelling of the thyroid gland (thyroiditis) and whose bodies do not produce enough levothyroxine for a short time. TIROSINT is unsuitable for children less than 6 years of age or who may be unable to swallow an intact capsule. | |||
Do not take TIROSINT:
| |||
Before you take TIROSINT, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. TIROSINT may affect the way other medicines work, and other medicines may affect how TIROSINT works. You can ask your doctor or pharmacist for a list of medicines that interact with TIROSINT. | |||
How should I take TIROSINT?
| |||
| What are the possible side effects of TIROSINT? TIROSINT may cause serious side effects, including:
The most common side effects of TIROSINT include: | |||
|
|
| |
Other side effects may include:
These are not all the possible side effects of TIROSINT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Akrimax Pharmaceuticals at 1-888-383-1733 or | |||
How should I store TIROSINT?
Keep TIROSINT and all medicines out of the reach of children. | |||
| General information about the safe and effective use of TIROSINT Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TIROSINT for a condition for which it was not prescribed. Do not give TIROSINT to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or doctor for information about TIROSINT that is written for health professionals. | |||
| What are the ingredients in TIROSINT? Active ingredient: levothyroxine sodium Inactive ingredients: gelatin, glycerin, and water Manufactured by: Institut Biochimique SA (IBSA). 6915 Pambio-Noranco Switzerland; Marketed and distributed by: Akrimax Pharmaceuticals, LLC, Cranford, NJ 07016 USA For more information, go to | |||
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-490-84
13 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-491-84
25 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-492-84
50 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-493-84
75 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-494-84
88 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-495-84
100 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-496-84
112 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-497-84
125 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-498-84
137 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-499-84
150 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-500-84
175 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
TIROSINT®
(levothyroxine sodium) capsules
NDC 24090-501-84
200 mcg
per capsule
Rx Only
Do not remove individual capsules from blister packaging until ready to use
AKRIMAX
PHARMACEUTICALS
4 blisters x 7 capsules
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 24090-490-84 | EA - Each | 24090-490 | 5bd23fae-19d6-4c24-9b67-7c8e9a8847df | 1 | 2012-07-24 |
| 24090-491-84 | EA - Each | 24090-491 | 6c09424e-84a5-4f57-89b3-41f3f790a698 | 1 | 2012-07-24 |
| 24090-492-84 | EA - Each | 24090-492 | bfc0b721-5865-43a4-b175-639fa9bac086 | 1 | 2012-07-24 |
| 24090-493-84 | EA - Each | 24090-493 | 37b118ea-e48b-4bb2-8831-7a9b732e4298 | 1 | 2012-07-24 |
| 24090-494-84 | EA - Each | 24090-494 | 79f559e6-0d47-4d9a-b71f-efbfc157b3a6 | 1 | 2012-07-24 |
| 24090-495-84 | EA - Each | 24090-495 | 57529ff7-1e7a-4e02-9669-b275303bbf53 | 1 | 2012-07-24 |
| 24090-496-84 | EA - Each | 24090-496 | 79107f99-7469-4235-9512-68b71f8fbb64 | 1 | 2012-07-24 |
| 24090-497-84 | EA - Each | 24090-497 | 5a0f4ce9-8fbf-45ca-a20f-d877b2a2fe01 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Levothyroxine Sodium | ACTIVE INGREDIENT | 9J765S329G | 12 | |
| Levothyroxine | ACTIVE MOIETY | Q51BO43MG4 | 12 | |
| Gelatin | INACTIVE INGREDIENT | 2G86QN327L | 12 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 12 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 12 |
Every source-derived product name is available through these pages.
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE / ORAL | 3487 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| Gelatin | GELATIN | 2G86QN327L | CAPSULE, COATED PELLETS / ORAL | 65 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| Gelatin | GELATIN | 2G86QN327L | CAPSULE, LIQUID FILLED / ORAL | 1042 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 1 mg | ||
| Gelatin | GELATIN | 2G86QN327L | CAPSULE, COATED / ORAL | 288 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET / ORAL | 46 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| Gelatin | GELATIN | 2G86QN327L | SYRUP / ORAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET, EXTENDED RELEASE / ORAL | 239 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET / PERIODONTAL | 3.44 mg | ||
| Gelatin | GELATIN | 2G86QN327L | POWDER / ORAL | 100 mg | ||
| Gelatin | GELATIN | 2G86QN327L | PASTE / DENTAL | 252 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION / INTRAVENOUS | 20 mg | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET, SUGAR COATED / ORAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 14 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 14 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET / SUBLINGUAL | 19 mg | ||
| Gelatin | GELATIN | 2G86QN327L | CAPSULE / ORAL | 10932 mg | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION / INTRACAVITARY | 0.05 ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET, COATED / ORAL | 42.12 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SUSPENSION / INTRAMUSCULAR | 2 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| Gelatin | GELATIN | 2G86QN327L | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| Gelatin | GELATIN | 2G86QN327L | CAPSULE, EXTENDED RELEASE / ORAL | 1229 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| Gelatin | GELATIN | 2G86QN327L | POWDER / RESPIRATORY (INHALATION) | 100 mg | ||
| Gelatin | GELATIN | 2G86QN327L | SOLUTION / INTRAVENOUS | 34.8 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, COATED / ORAL | 1 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET, ORALLY DISINTEGRATING / ORAL | 120 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021924-002 | TIROSINT | LEVOTHYROXINE SODIUM | 0.025MG | CAPSULE / ORAL | RLD | 2006-10-13 | |
| N021924-003 | TIROSINT | LEVOTHYROXINE SODIUM | 0.05MG | CAPSULE / ORAL | RLD | 2006-10-13 | |
| N021924-004 | TIROSINT | LEVOTHYROXINE SODIUM | 0.075MG | CAPSULE / ORAL | RLD | 2006-10-13 | |
| N021924-005 | TIROSINT | LEVOTHYROXINE SODIUM | 0.1MG | CAPSULE / ORAL | RLD | 2006-10-13 | |
| N021924-006 | TIROSINT | LEVOTHYROXINE SODIUM | 0.125MG | CAPSULE / ORAL | RLD | 2006-10-13 | |
| N021924-007 | TIROSINT | LEVOTHYROXINE SODIUM | 0.15MG | CAPSULE / ORAL | RLD | 2006-10-13 | |
| N021924-008 | TIROSINT | LEVOTHYROXINE SODIUM | 0.112MG | CAPSULE / ORAL | RLD | 2009-10-02 | |
| N021924-009 | TIROSINT | LEVOTHYROXINE SODIUM | 0.137MG | CAPSULE / ORAL | RLD | 2009-10-02 | |
| N021924-010 | TIROSINT | LEVOTHYROXINE SODIUM | 0.088MG | CAPSULE / ORAL | RLD | 2009-10-02 | |
| N021924-011 | TIROSINT | LEVOTHYROXINE SODIUM | 0.175MG | CAPSULE / ORAL | RLD | 2017-04-25 | |
| N021924-012 | TIROSINT | LEVOTHYROXINE SODIUM | 0.2MG | CAPSULE / ORAL | RLD, RS | 2017-04-25 | |
| N021924-013 | TIROSINT | LEVOTHYROXINE SODIUM | 0.013MG | CAPSULE / ORAL | RLD | 2007-08-01 | |
| N021924-014 | TIROSINT | LEVOTHYROXINE SODIUM | 0.0375MG | CAPSULE / ORAL | RLD | 2022-06-22 | |
| N021924-015 | TIROSINT | LEVOTHYROXINE SODIUM | 0.044MG | CAPSULE / ORAL | RLD | 2022-06-22 | |
| N021924-016 | TIROSINT | LEVOTHYROXINE SODIUM | 0.0625MG | CAPSULE / ORAL | RLD | 2022-06-22 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N021924-002 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-003 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-004 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-005 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-006 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-007 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-008 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-009 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-010 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-011 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-012 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-013 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-014 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-015 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | |
| N021924-016 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021924-002 | TIROSINT | 0.025MG | CAPSULE / ORAL | RLD | 2006-10-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-003 | TIROSINT | 0.05MG | CAPSULE / ORAL | RLD | 2006-10-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-004 | TIROSINT | 0.075MG | CAPSULE / ORAL | RLD | 2006-10-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-005 | TIROSINT | 0.1MG | CAPSULE / ORAL | RLD | 2006-10-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-006 | TIROSINT | 0.125MG | CAPSULE / ORAL | RLD | 2006-10-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-007 | TIROSINT | 0.15MG | CAPSULE / ORAL | RLD | 2006-10-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-008 | TIROSINT | 0.112MG | CAPSULE / ORAL | RLD | 2009-10-02 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-009 | TIROSINT | 0.137MG | CAPSULE / ORAL | RLD | 2009-10-02 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-010 | TIROSINT | 0.088MG | CAPSULE / ORAL | RLD | 2009-10-02 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-011 | TIROSINT | 0.175MG | CAPSULE / ORAL | RLD | 2017-04-25 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-012 | TIROSINT | 0.2MG | CAPSULE / ORAL | RLD, RS | 2017-04-25 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-013 | TIROSINT | 0.013MG | CAPSULE / ORAL | RLD | 2007-08-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-014 | TIROSINT | 0.0375MG | CAPSULE / ORAL | RLD | 2022-06-22 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-015 | TIROSINT | 0.044MG | CAPSULE / ORAL | RLD | 2022-06-22 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-016 | TIROSINT | 0.0625MG | CAPSULE / ORAL | RLD | 2022-06-22 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-002 | TIROSINT | 0.025MG | CAPSULE / ORAL | RLD | 2006-10-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-003 | TIROSINT | 0.05MG | CAPSULE / ORAL | RLD | 2006-10-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-004 | TIROSINT | 0.075MG | CAPSULE / ORAL | RLD | 2006-10-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-005 | TIROSINT | 0.1MG | CAPSULE / ORAL | RLD | 2006-10-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-006 | TIROSINT | 0.125MG | CAPSULE / ORAL | RLD | 2006-10-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-007 | TIROSINT | 0.15MG | CAPSULE / ORAL | RLD | 2006-10-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-008 | TIROSINT | 0.112MG | CAPSULE / ORAL | RLD | 2009-10-02 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-009 | TIROSINT | 0.137MG | CAPSULE / ORAL | RLD | 2009-10-02 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-010 | TIROSINT | 0.088MG | CAPSULE / ORAL | RLD | 2009-10-02 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-011 | TIROSINT | 0.175MG | CAPSULE / ORAL | RLD | 2017-04-25 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-012 | TIROSINT | 0.2MG | CAPSULE / ORAL | RLD, RS | 2017-04-25 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-013 | TIROSINT | 0.013MG | CAPSULE / ORAL | RLD | 2007-08-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-014 | TIROSINT | 0.0375MG | CAPSULE / ORAL | RLD | 2022-06-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-015 | TIROSINT | 0.044MG | CAPSULE / ORAL | RLD | 2022-06-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-016 | TIROSINT | 0.0625MG | CAPSULE / ORAL | RLD | 2022-06-22 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-002 | TIROSINT | 0.025MG | CAPSULE / ORAL | RLD | 2006-10-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-003 | TIROSINT | 0.05MG | CAPSULE / ORAL | RLD | 2006-10-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-004 | TIROSINT | 0.075MG | CAPSULE / ORAL | RLD | 2006-10-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-005 | TIROSINT | 0.1MG | CAPSULE / ORAL | RLD | 2006-10-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-006 | TIROSINT | 0.125MG | CAPSULE / ORAL | RLD | 2006-10-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-007 | TIROSINT | 0.15MG | CAPSULE / ORAL | RLD | 2006-10-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-008 | TIROSINT | 0.112MG | CAPSULE / ORAL | RLD | 2009-10-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-009 | TIROSINT | 0.137MG | CAPSULE / ORAL | RLD | 2009-10-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-010 | TIROSINT | 0.088MG | CAPSULE / ORAL | RLD | 2009-10-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-011 | TIROSINT | 0.175MG | CAPSULE / ORAL | RLD | 2017-04-25 | caaa826d4ba7… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2021-12-28 21:50 UTC | 2021-12 | N021924-008 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021924-004 | AB | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021924-005 | AB | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021924-006 | AB | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021924-007 | AB | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021924-010 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N021924-004 | AB | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | N021924-005 | AB | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | N021924-006 | AB | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | N021924-007 | AB | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | N021924-010 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N021924-004 | AB | 1 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | N021924-007 | AB | 1 | 8869cabd3fbd… |
| 2023-05-13 08:27 UTC | 2023-05 | N021924-012 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N021924-012 | AB | 1 | 3bdfa0b2c4d7… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021924-002 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-003 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-004 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-005 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-006 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-007 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-008 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-009 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-010 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-011 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-012 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-013 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-014 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-015 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021924-016 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-002 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-003 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-004 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-005 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-006 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-007 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-008 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-009 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-010 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-011 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-012 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-013 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-014 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-015 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021924-016 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-002 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-003 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-004 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-005 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-006 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-007 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-008 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-009 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-010 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021924-011 | 12564565 | 2044-09-26 | Drug product | 2026-03-20 | caaa826d4ba7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 20b8899d-7692-4149-b5a2-80368cc08355 | f4d851f6-6bf5-4ed5-8d3a-1646773c4d40 | 2020-09-01 | Boxed warning, Warnings, Adverse reactions | f4d851f6-6bf5-4ed5-8d3a-1646773c4d40 |
Adverse event summaries are temporarily unavailable. Other product information remains available.